Blackrock Neurotech’s MoveAgain Brain-Computer Interface System Receives Breakthrough Device Designation from the FDA

Summation

  • To qualify for the Breakthrough Device designation, a device must represent a novel application of an existing technology, and show that it has the potential to provide for more effective treatment of irreversibly debilitating diseases or conditions.
  • The goal of the device is to achieve long-term improvement in movement and independence, reduce patient reliance on caregivers and help them better engage with society and the world.
  • “We look forward to working closely with the FDA to prioritize development of the MoveAgain Brain-Computer Interface System, which will bring us closer to our goal of commercialization in 2022.

Blackrock Neurotech, the leader in brain-computer interface technology, today announces that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation for its groundbreaking MoveAgain Brain Computer Interface (BCI) System.

The first-of-its-kind system is expected to provide immobile patients the ability to control a mouse cursor, keyboard, mobile device/tablet, wheelchair or prosthetic device simply by thinking.
The FDA Breakthrough Device designation aims to expedite the review of innovative technologies that can improve the lives of people with irreversibly debilitating diseases or conditions. Approximately 5.35 million people in the United States live with some form of paralysis as a result of central nervous system disorders, autoimmune diseases and spinal cord injuries (SCIs). Many of these patients are completely dependent on permanent support from a caretaker, and their ability to communicate or control their external environment is severely limited.
Blackrock’s portable MoveAgain BCI could offer these patients new possibilities for improved mobility and independence – such as returning to work, participating in leisure activities, and communicating more effectively and quickly. The goal of the device is to achieve long-term improvement in movement and independence, reduce patient reliance on caregivers and help them better engage with society and the world.
“We look forward to working closely with the FDA to prioritize development of the MoveAgain Brain-Computer Interface System, which will bring us closer to our goal of commercialization in 2022.  Patients with tetraplegia are eager to get access, and we are committed to advancing their ability to increase their independence with our BCI technology,” said Marcus Gerhardt, co-founder and CEO of Blackrock Neurotech.
The MoveAgain BCI system is built upon 25 years of groundbreaking clinical research in humans conducted by a number of leading institutions. The system consists of an array implanted in the brain, which decodes intended movement from neuronal activity. Those signals are then transmitted wirelessly to an external device, such as a cursor or wheelchair, providing people with control of their external environment.
“We are very grateful that commercialization of these life-changing products is now possible.,” said Florian Solzbacher, Chairman and President of Blackrock Neurotech. “We are confident we have sufficient safety and efficacy data to support the first applications, and very large-scale integration technologies have allowed further miniaturization, which will make a robust wireless version possible. We look forward to submitting plans to make these products widely available in 2022.
To qualify for the Breakthrough Device designation, a device must represent a novel application of an existing technology, and show that it has the potential to provide for more effective treatment of irreversibly debilitating diseases or conditions. The goal of the program is to provide patients and clinicians more timely access to these breakthrough devices by accelerating their development, assessment, and review, while preserving statutory standards for pre-market approval.
“We are seeing the beginning of a revolution in the diagnosis and treatment of neurological disorders and disabilities,” said Solzbacher. “Ten years from now, neural implants could be as common as cardiac pacemakers are today — offering patients a whole new world of options that restore their independence.”
1 Early research began at the University of Utah and Braingate; see: https://www.nature.com/articles/nature04970
2 University of Pittsburgh, Brown University, Massachusetts General Hospital, John Hopkins University, Ohio State University, Battelle Memorial Institute,  Case Western Reserve University, Wyss Center, University of Geneva, TU Munich, Thomas Jefferson University, California Institute of Technology, Rancho Los Amigos National Rehabilitation Center, University of Southern California, University of California Los Angeles, Casa Colina Centers for Rehabilitation, Stanford University, Zhejiang University, The University of Chicago, Providence VA Medical Center, Louis Stokes VA Medical Center,  Fundación Tecnalia Research & Innovation: San Sebastian, University Miguel Hernandez, Elche, Spain,  and others.

Other FDA News of Interest

Tris Pharma Receives U.S. FDA Approval for Once-Daily ONYDA XR (clonidine hydrochloride) Extended-Release Oral Suspension, the First-and-Only Liquid Non-Stimulant ADHD Medication

ONYDA XR is indicated for the treatment of ADHD as monotherapy or as adjunctive therapy to approved CNS stimulant medications in pediatric patients six years and older. The first non-stimulant ADHD medication, with nighttime dosing, adds to Tris Pharma’s established portfolio of leading ADHD therapies and reinforces company's commitment to individuals with ADHD.

Indica Labs Receives FDA Clearance for HALO AP Dx Digital Pathology Platform for Use with Hamamatsu Images Acquired with the NanoZoomer® S360MD Slide Scanner

Indica Labs, an industry leader in AI-powered digital pathology solutions, and Hamamatsu Photonics K.K., a pioneer in whole slide imaging systems, announce that the...

FDA Grants AI-Powered Notal Vision Home OCT “SCANLY” De Novo Marketing Authorization

“We are very excited to receive FDA authorization to market SCANLY Home OCT as the first-ever patient self-operated, home-use device that gives physicians remote access to high-resolution, cross-sectional retinal images and AI-based analytical biomarkers of their patients eyes between office visits,” said Kester Nahen, PhD, CEO of Notal Vision. “We look forward to supporting our referring physicians in navigating their wet AMD patients’ care.”

By using this website you agree to accept Medical Device News Magazine Privacy Policy